In a report released today, Naureen Quibria from Capital One Financial reiterated a Buy rating on Fennec Pharmaceuticals (FENC – Research Report), with a price target of $16.00. The company’s shares opened today at $10.75.
Quibria covers the Healthcare sector, focusing on stocks such as Chimerix, Fennec Pharmaceuticals, and ADC Therapeutics. According to TipRanks, Quibria has an average return of -23.0% and a 22.55% success rate on recommended stocks.
Currently, the analyst consensus on Fennec Pharmaceuticals is a Moderate Buy with an average price target of $8.55.
See today’s best-performing stocks on TipRanks >>
Based on Fennec Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $6.52 million and a GAAP net loss of $1.87 million. In comparison, last year the company had a GAAP net loss of $8.09 million
Based on the recent corporate insider activity of 19 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Fennec Pharmaceuticals (FENC) Company Description:
Fennec Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development of sodium thiosulfate for the prevention of ototoxicity from cisplatin in pediatric cancer patients. The company was founded by Orest W. Blaschuk on September 3, 1996 and is headquartered in Durham, NC.
Read More on FENC:
- Fennec Pharmaceuticals Strikes Major European Deal
- Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand
- Fennec sees FY23 revenue $20.7M-$21.2M, consensus $19.57M
- Fennec sees Q4 revenue $9.2M-$9.7M, consensus $8.06M
- Fennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 Results
